TARGET FIRST is a prospective, international, multicentre, open-label, randomized (1:1) post-market study to evaluate a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy. The...
Single-arm, Prospective, Open label, All Comers, Multicenter Registry. The objective is to collect and evaluate clinical data regarding the safety and performance of the Support C in a real-world setting (in clinical routine)
Single-arm, Prospective, Open label, All Comers, Multicenter Registry. The objective is to assess safety and performance of EucaLimus, a sirolimus eluting PTCA stent system, in a prospective study as part of the manufacturer‘s post-market surveillance program
ABILITY DIABETES GLOBAL is a prospective, multi-center, multinational, randomized, open label (follow-ups blinded), 2-arm parallel groups study. The objective is to compare in diabetic patients eligible for percutaneous coronary intervention (PCI) with minimal exclusion criteria, the efficacy and...
A Prospective Randomized (1:1), Multi-center, International, Open label Clinical trial. The objective is to demonstrate non-inferiority for Target Vessel Failure (TVF) of a treatment strategy with first line SELUTION SLR Drug Eluting Balloon (DEB) plus provisional Drug Eluting Stent (DES) vs...
SAITO1B is prospective, single arm, First-In-Human study. The objective is to assess the feasibility and safety of the TaviPilot augmented reality guidance software during TAVI procedures, aiming to improve valve positioning precision and, implicitly, reduce implantation depth variations in patients...
SAITO1A is single center, prospective, single arm, First-In-Human study. The objective is to assess the feasibility and safety of the TaviPilot augmented reality guidance software during TAVI procedures, aiming to improve valve positioning precision and, implicitly, reduce implantation depth...
An international, multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) clinical investigation to evaluate the clinical safety and effectiveness of the Coroflex® ISAR NEO stent for the treatment of coronary disease.
RESTORE is a single arm, prospective, multicentre, pilot study to evaluate the safety and performance of AdvaPro Sirolimus Eluting Coronary Stent System in Coronary Artery Stenosis in Indian and European Population. A total of 120 subjects will be recruited across France and India, with...
MAGICAL SV is a prospective, multi-center, multinational, randomized, single-blind, pivotal, 2-arm parallel groups study. The objective is to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels (≤2.75 mm) in patients with coronary artery disease. A...
